Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks Settle Mixed on Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.10%....

PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
TXN : 182.54 (+1.34%)
$IUXX : 25,692.05 (+0.43%)
SAIC : 100.61 (-1.16%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-145 (-0.06%)
COST : 894.68 (-0.13%)
FIVE : 173.20 (+2.84%)
ESZ25 : 6,888.50 (+0.15%)
GFS : 38.95 (+3.65%)
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering...

HALO : 63.33 (+0.60%)
Stocks Pressured as Bond Yields Rise and Chip Stocks Fall

The S&P 500 Index ($SPX ) (SPY ) is down by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.28%. December E-mini S&P futures...

PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
BF.B : 30.40 (+2.36%)
$IUXX : 25,692.05 (+0.43%)
SAIC : 100.61 (-1.16%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-145 (-0.06%)
COST : 894.68 (-0.13%)
ESZ25 : 6,888.50 (+0.15%)
GFS : 38.95 (+3.65%)
LRCX : 158.70 (+1.02%)
Stocks Pressured by Higher Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is down up by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.38%. December E-mini S&P...

MSTR : 178.99 (-3.77%)
PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
GLXY : 25.51 (-7.47%)
BF.B : 30.40 (+2.36%)
$IUXX : 25,692.05 (+0.43%)
COIN : 269.73 (-1.58%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-145 (-0.06%)
FIVE : 173.20 (+2.84%)
ESZ25 : 6,888.50 (+0.15%)
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host...

HALO : 63.33 (+0.60%)
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Royalty revenue contribution expected to begin as early as 2030

HALO : 63.33 (+0.60%)
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.  (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific...

MRUS : 96.14 (-0.08%)
HALO : 63.33 (+0.60%)
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology

HALO : 63.33 (+0.60%)
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of 0% convertible...

HALO : 63.33 (+0.60%)
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other...

HALO : 63.33 (+0.60%)

Barchart Exclusives

Option Volatility and Earnings Report for December 8 - 12
Earnings season is starting to wind down but we still have some big names due to report Q3 numbers. This week, we have Costco (COST), Broadcom (AVGO), Adobe Systems (ADBE) and Oracle (ORCL) all set to report. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar